WCN26-3083 SGLT2 inhibitor prevents loop diuretic–induced plasma volume loss through a vasopressin-independent thirst-stimulating mechanism

Read full text Summarise with VIRAT
Authors: Takahiro Masuda, Masahide Yoshida, Tatsushi Onaka, Daisuke Nagata, Yoshiyuki Morishita
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

SGLT2 inhibitors promote euvolemic fluid maintenance through activation of vasopressin (AVP) and compensatory water intake during osmotic diuresis, whereas loop diuretics suppress AVP and lead to hypovolemia (Physiol Rep 2020, AJP Renal 2022). We recently reported that SGLT2 inhibitor–loop diuretic combination therapy preserves body fluid balance in chronic kidney disease (Front Med 2023, Diagnostics 2024), but the underlying mechanism remains unclear.

Fields of Study & Subjects

Electrolyte and hormonal disorders Diabetes Treatment and Management Ion Transport and Channel Regulation

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104434–104434
Publication date
25 March 2026
Language
EN